From a Solitary Blood-Derived Biomarker to Combined Biomarkers of Sarcopenia: Experiences From the Korean Frailty and Aging Cohort Study
- 17 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (6)
Abstract
Sarcopenia is recognized as a complex and multifactorial disorder that includes nutritional deficiency, inactivity, proinflammatory status, hormonal changes, neurological degeneration, and metabolic disturbances. It’s pathogenesis is not fully understood. Therefore, identifying specific biomarkers of sarcopenia will help us understand its pathophysiology. The most frequently reported blood-derived biomarkers of sarcopenia are growth factors, neuromuscular junctions, endocrine systems, mitochondrial dysfunction, inflammation-mediated and redox processes, muscle protein turnover, blood metabolomics, and behavior-mediated biomarkers. Here, we address the implications of sarcopenia biomarkers based on our research experience with Korean Frailty and Aging Cohort Study cohort data. It includes free testosterone, myostatin, fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15), procollagen type III N-terminal peptide (P3NP), creatinine-based biomarkers, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), brain-derived neurotrophic factor (BDNF), metabolites (proline, alanine, tryptophan), and multi-biomarker risk score. We attempted to explain the paradoxical findings of myostatin and FGF-21 levels in relation to sarcopenia. GDF-15 levels were associated with sarcopenia prevalence but not its incidence. Plasma P3NP and BDNF levels may be biomarkers of muscle quality rather than quantity. Lower erythrocyte eicosapentaenoic acid (EPA) and docosahexaenoic acid levels were associated with slow gait speed, and erythrocyte EPA levels were associated with low handgrip strength. We developed a multi-biomarker risk score for sarcopenia and found that its accuracy in diagnosing sarcopenia was higher than that of any single biomarker.Keywords
Funding Information
- Ministry of Health and Welfare, Republic of Korea (HI15C3153)
- National Institute of Health, Korea Disease Control and Prevention Agency (2021-ER0605-00)
This publication has 73 references indexed in Scilit:
- Muscle quality, physical performance, and comorbidity are predicted by circulating procollagen type III N-terminal peptide (P3NP): the InCHIANTI follow-up studyGeroScience, 2023
- Fatty acid amides as potential circulating biomarkers for sarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2023
- Relationships between cystatin C and creatinine‐based eGFR with low tongue pressure in Japanese rural community‐dwelling older adultsClinical and Experimental Dental Research, 2022
- Serum creatinine and cystatin C‐based diagnostic indices for sarcopenia in advanced non‐small cell lung cancerJournal of Cachexia, Sarcopenia and Muscle, 2022
- Identification of traumatic acid as a potential plasma biomarker for sarcopenia using a metabolomics‐based approachJournal of Cachexia, Sarcopenia and Muscle, 2021
- Proline metabolism and redox; maintaining a balance in health and diseaseAmino Acids, 2021
- Dietary tryptophan and bone health: a cross-sectional, population-based studyArchives of Osteoporosis, 2020
- Looking for Sarcopenia BiomarkersThe American Journal of Medicine, 2017
- Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinaseDiabetologia, 2009
- Limitations of Serum Creatinine Level and Creatinine Clearance as Filtration Markers in CirrhosisArchives of internal medicine (1960), 1994